Integra LifeSciences - IART Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $44.89
  • Forecasted Upside: 41.92%
  • Number of Analysts: 9
  • Breakdown:
  • 2 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.31 (-0.97%)

This chart shows the closing price for IART by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Integra LifeSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IART and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IART

Analyst Price Target is $44.89
▲ +41.92% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Integra LifeSciences in the last 3 months. The average price target is $44.89, with a high forecast of $53.00 and a low forecast of $37.00. The average price target represents a 41.92% upside from the last price of $31.63.

This chart shows the closing price for IART for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Integra LifeSciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/3/2024CitigroupUpgradeSell ➝ Neutral$38.00Low
3/1/2024Truist FinancialLower TargetHold ➝ Hold$46.00 ➝ $41.00Low
2/29/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$55.00 ➝ $49.00Low
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$44.00 ➝ $46.00Low
12/14/2023Truist FinancialBoost TargetHold ➝ Hold$39.00 ➝ $44.00Low
12/14/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$55.00Low
12/5/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$40.00 ➝ $49.00Low
11/14/2023CL KingInitiated CoverageBuy$50.00Low
10/26/2023Truist FinancialLower TargetHold ➝ Hold$41.00 ➝ $39.00Low
10/26/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$44.00 ➝ $37.00Low
8/24/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$44.00Low
7/28/2023JMP SecuritiesLower TargetOutperform$65.00 ➝ $60.00Low
7/19/2023Truist FinancialBoost Target$44.00 ➝ $48.00Low
7/12/2023Jefferies Financial GroupUpgradeHold ➝ Buy$58.00 ➝ $53.00Low
6/26/2023Piper SandlerLower Target$55.00 ➝ $44.00Low
6/8/2023ArgusDowngradeBuy ➝ HoldLow
5/30/2023Truist FinancialLower Target$54.00 ➝ $44.00Low
5/24/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$56.00 ➝ $43.00Low
5/23/202322nd Century GroupReiterated RatingDowngradeLow
5/23/2023CitigroupDowngradeNeutral ➝ Sell$59.00 ➝ $39.00Low
5/18/2023Truist FinancialLower Target$58.00 ➝ $54.00Low
4/27/2023JMP SecuritiesLower Target$75.00 ➝ $65.00Low
4/17/2023Truist FinancialBoost TargetHold$58.00 ➝ $62.00Low
2/23/2023CitigroupLower TargetNeutral$60.00 ➝ $59.00Low
1/6/2023Morgan StanleyBoost TargetEqual Weight$50.00 ➝ $59.00Low
12/20/2022Truist FinancialBoost TargetHold$52.00 ➝ $58.00Low
12/12/2022CitigroupBoost TargetNeutral$50.00 ➝ $60.00Low
10/27/2022Morgan StanleyBoost TargetEqual Weight$49.00 ➝ $50.00Low
10/27/2022JMP SecuritiesLower TargetMarket Outperform$85.00 ➝ $75.00N/A
10/17/2022Truist FinancialLower TargetHold$60.00 ➝ $46.00Low
10/11/2022Jefferies Financial GroupInitiated CoverageHold$48.00Low
10/11/2022Morgan StanleyLower TargetEqual Weight$58.00 ➝ $49.00Low
10/5/2022CitigroupLower Target$57.00 ➝ $50.00Low
8/25/2022Morgan StanleyLower TargetEqual Weight$59.00 ➝ $58.00Low
8/24/2022Piper SandlerLower Target$55.00 ➝ $50.00Low
7/27/2022Piper SandlerLower Target$66.00 ➝ $55.00Low
7/25/2022Morgan StanleyInitiated CoverageEqual Weight$59.00Low
7/20/2022Truist FinancialLower TargetHold$70.00 ➝ $56.00Low
5/17/2022CitigroupLower TargetNeutral$70.00 ➝ $67.00N/A
4/13/2022Truist FinancialDowngradeBuy ➝ Hold$72.00 ➝ $71.00Low
2/23/2022Piper SandlerLower Target$72.00 ➝ $66.00Medium
1/18/2022Bank of AmericaBoost TargetUnderperform$55.00 ➝ $65.00Low
12/17/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$75.00High
11/3/2021Credit Suisse GroupBoost TargetOutperform$84.00 ➝ $87.00Low
11/3/2021JMP SecuritiesReiterated RatingBuyLow
9/15/2021BTIG ResearchDowngradeBuy ➝ NeutralLow
6/24/2021Raymond JamesReiterated RatingHoldHigh
4/29/2021CitigroupBoost Target$70.00 ➝ $78.00Low
4/29/2021Wells Fargo & CompanyBoost TargetEqual Weight$68.00 ➝ $74.00Medium
4/29/2021OppenheimerBoost TargetOutperform$79.00 ➝ $88.00Medium
2/25/2021Credit Suisse GroupBoost TargetOutperform$73.00 ➝ $79.00Medium
2/19/2021CitigroupBoost Target$60.00 ➝ $70.00Low
1/29/2021Piper SandlerBoost TargetNeutral$47.00 ➝ $65.00High
1/27/2021JMP SecuritiesBoost TargetOutperform$65.00 ➝ $80.00High
1/19/2021BTIG ResearchBoost TargetBuy$66.00 ➝ $72.00High
1/7/2021Credit Suisse GroupBoost TargetPositive ➝ Outperform$60.00 ➝ $73.00N/A
1/6/2021Truist FinancialBoost Target$60.00 ➝ $70.00N/A
12/17/2020OppenheimerBoost Target$64.00 ➝ $72.00Low
12/17/2020BTIG ResearchBoost TargetBuy$59.00 ➝ $66.00Medium
10/29/2020Piper SandlerLower TargetNeutral$53.00 ➝ $47.00Low
10/29/2020OppenheimerInitiated CoverageBuy$64.00Medium
10/8/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$55.00 ➝ $50.00High
9/30/2020Raymond JamesReiterated RatingHoldMedium
9/29/2020OppenheimerReiterated RatingBuy$68.00Medium
8/12/2020Truist FinancialBoost Target$55.00 ➝ $60.00Low
8/11/2020Credit Suisse GroupBoost TargetOutperform$58.00 ➝ $60.00High
8/11/2020UBS GroupBoost TargetNeutral$51.00 ➝ $53.00High
8/11/2020OppenheimerBoost TargetOutperform$60.00 ➝ $68.00High
7/10/2020Credit Suisse GroupReiterated RatingBuy$58.00Low
6/26/2020Credit Suisse GroupReiterated RatingBuy$58.00High
5/27/2020CitigroupInitiated CoverageNeutral$54.00Low
5/8/2020UBS GroupLower TargetNeutral$65.00 ➝ $55.00Low
5/8/2020Credit Suisse GroupBoost TargetOutperform$56.00 ➝ $58.00Low
5/8/2020JMP SecuritiesLower TargetMarket Outperform$75.00 ➝ $65.00Low
5/7/2020BTIG ResearchReiterated RatingBuyMedium
4/8/2020BTIG ResearchLower TargetBuy$70.00 ➝ $59.00High
4/7/2020Piper SandlerReiterated RatingHold$58.00High
4/6/2020Wells Fargo & CompanyLower TargetEqual Weight$62.00 ➝ $46.00High
4/2/2020SunTrust BanksInitiated CoverageBuy$55.00Medium
3/6/2020Credit Suisse GroupLower TargetOutperform$70.00 ➝ $65.00Low
2/20/2020UBS GroupBoost TargetNeutral$64.00 ➝ $65.00Medium
1/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$59.00 ➝ $58.00Low
1/7/2020Piper Sandler CompaniesDowngradeOverweight ➝ Neutral$59.00 ➝ $58.00Low
1/3/2020SunTrust BanksInitiated CoverageBuy$56.00Low
12/18/2019UBS GroupBoost TargetNeutral$63.00 ➝ $65.00Low
10/25/2019OppenheimerSet TargetBuy$68.00N/A
10/25/2019Royal Bank of CanadaSet TargetHold$62.00N/A
10/25/2019Wells Fargo & CompanySet TargetHold$62.00N/A
10/8/2019Wells Fargo & CompanyLower TargetMarket Perform$68.00 ➝ $65.00High
7/26/2019Royal Bank of CanadaSet TargetHold$66.00Low
7/25/2019OppenheimerBoost TargetOutperform$65.00 ➝ $70.00Medium
7/25/2019Wells Fargo & CompanyBoost TargetMarket Perform$55.00 ➝ $68.00Medium
7/25/2019JMP SecuritiesBoost Target$75.00Medium
7/24/2019BTIG ResearchSet TargetBuy$70.00Low
4/25/2019OppenheimerLower TargetOutperform$70.00 ➝ $65.00Low
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 6 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 6 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 12 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 7 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 7 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Integra LifeSciences logo
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $31.63
Low: $31.47
High: $32.08

50 Day Range

MA: $37.12
Low: $31.63
High: $45.20

52 Week Range

Now: $31.63
Low: $31.47
High: $59.10


508,410 shs

Average Volume

645,789 shs

Market Capitalization

$2.49 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Integra LifeSciences?

The following Wall Street analysts have issued reports on Integra LifeSciences in the last year: 22nd Century Group, Inc., Argus, Citigroup Inc., CL King, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler,, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for IART.

What is the current price target for Integra LifeSciences?

9 Wall Street analysts have set twelve-month price targets for Integra LifeSciences in the last year. Their average twelve-month price target is $44.89, suggesting a possible upside of 42.4%. Jefferies Financial Group Inc. has the highest price target set, predicting IART will reach $53.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $37.00 for Integra LifeSciences in the next year.
View the latest price targets for IART.

What is the current consensus analyst rating for Integra LifeSciences?

Integra LifeSciences currently has 2 sell ratings, 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IART, but not buy more shares or sell existing shares.
View the latest ratings for IART.

What other companies compete with Integra LifeSciences?

Other companies that are similar to Integra LifeSciences include Alphatec, AtriCure, Globus Medical, Teleflex and PROCEPT BioRobotics. Learn More about companies similar to Integra LifeSciences.

How do I contact Integra LifeSciences' investor relations team?

Integra LifeSciences' physical mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company's listed phone number is (609) 275-0500 and its investor relations email address is [email protected]. The official website for Integra LifeSciences is Learn More about contacing Integra LifeSciences investor relations.